Why Bluebird Bio Stock Is Plunging Today
Shares of Bluebird Bio (NASDAQ: BLUE) were plunging 22.3% as of 10:41 a.m. ET on Monday. The big drop came after the company announced that the Food and Drug Administration (FDA) placed its clinical testing of lovo-cel in treating sickle cell disease on partial clinical hold. This partial clinical hold applies only to patients under age 18.
The FDA's decision is connected with Bluebird's ongoing investigation related to one adolescent patient who experienced persistent non-transfusion-dependent anemia after being treated with lovo-cel. Bluebird said that the patient is "clinically well" and added that there has been "no evidence of malignancy or clonal predominance."
Image source: Getty Images.
Source Fool.com
